On the public citation graph
The role of immunotherapy in small cell lung cancer
0 signed · 189 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-aopenalex-snapshot
The National Comprehensive Cancer Network
inferredcites →https://doi.org/10.1002/(sici)1097-0215(19970926)73:1<42::aid-ijc8>3.0.co;2-1openalex-snapshot
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides
inferredcites →https://doi.org/10.1007/s00262-011-1083-6openalex-snapshot
Immunization with N-propionyl polysialic acid–KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci
inferredcites →https://doi.org/10.1007/s00280-014-2427-7openalex-snapshot
Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)
inferredcites →https://doi.org/10.1007/s12094-010-0463-2openalex-snapshot
SEOM clinical guidelines for the treatment of small-cell lung cancer
inferredcites →https://doi.org/10.1007/s12094-010-0600-yopenalex-snapshot
Treatment of high-risk neuroblastoma with anti-GD2 antibodies
inferredcites →https://doi.org/10.1007/s40265-015-0399-5openalex-snapshot
Dinutuximab: First Global Approval
inferredcites →https://doi.org/10.1016/0169-5002(95)00583-8openalex-snapshot
Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomised trial
inferredcites →https://doi.org/10.1016/0959-8049(92)90526-8openalex-snapshot
Natural interferon alfa as maintenance therapy for small cell lung cancer
inferredcites →https://doi.org/10.1016/j.ccell.2018.04.001openalex-snapshot
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1016/j.ejca.2017.02.013openalex-snapshot
Cancer immunotherapy targeting the CD47/SIRPα axis
inferredcites →https://doi.org/10.1016/j.immuni.2013.07.012openalex-snapshot
Oncology Meets Immunology: The Cancer-Immunity Cycle
inferredcites →https://doi.org/10.1016/j.jtho.2016.05.028openalex-snapshot
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
inferredcites →https://doi.org/10.1016/j.jtho.2017.09.1040openalex-snapshot
P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC
inferredcites →https://doi.org/10.1016/j.jtho.2017.11.015openalex-snapshot
P2.04-002 CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
inferredcites →https://doi.org/10.1016/j.jtho.2018.05.002openalex-snapshot
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
inferredcites →https://doi.org/10.1016/j.jtho.2019.01.008openalex-snapshot
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
inferredcites →https://doi.org/10.1016/j.lungcan.2017.07.030openalex-snapshot
MHC class II expression in lung cancer
inferredcites →https://doi.org/10.1016/s0140-6736(05)76153-5openalex-snapshot
Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma
inferredcites →https://doi.org/10.1016/s0169-5002(97)00070-6openalex-snapshot
Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer:
inferredcites →https://doi.org/10.1016/s0959-8049(97)00174-3openalex-snapshot
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase iii study of the eortc lung cancer cooperative group
inferredcites →https://doi.org/10.1016/s1470-2045(16)30098-5openalex-snapshot
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30565-4openalex-snapshot
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
inferredcites →https://doi.org/10.1038/nature10673openalex-snapshot
Cancer immunotherapy comes of age
inferredcites →https://doi.org/10.1038/nature14664openalex-snapshot
Comprehensive genomic profiles of small cell lung cancer
inferredcites →https://doi.org/10.1038/ng.2396openalex-snapshot
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
inferredcites →https://doi.org/10.1038/nrc.2016.154openalex-snapshot
Targeting neoantigens to augment antitumour immunity
inferredcites →https://doi.org/10.1038/nrc.2017.87openalex-snapshot
Small-cell lung cancer: what we know, what we need to know and the path forward
inferredcites →https://doi.org/10.1038/nrc3239openalex-snapshot
The blockade of immune checkpoints in cancer immunotherapy
inferredcites →https://doi.org/10.1038/nrclinonc.2017.71openalex-snapshot
Unravelling the biology of SCLC: implications for therapy
inferredcites →https://doi.org/10.1038/nri3405openalex-snapshot
Molecular mechanisms of T cell co-stimulation and co-inhibition
inferredcites →https://doi.org/10.1056/nejmoa1809064openalex-snapshot
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1073/pnas.1121623109openalex-snapshot
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
inferredcites →https://doi.org/10.1073/pnas.93.10.4529openalex-snapshot
Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain.
inferredcites →https://doi.org/10.1084/jem.161.5.1135openalex-snapshot
Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.
inferredcites →https://doi.org/10.1084/jem.186.5.695openalex-snapshot
Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes
inferredcites →https://doi.org/10.1089/nat.2015.0533openalex-snapshot
Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703
inferredcites →https://doi.org/10.1093/annonc/mds213openalex-snapshot
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
inferredcites →https://doi.org/10.1093/annonc/mdt178openalex-snapshot
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
inferredcites →https://doi.org/10.1093/annonc/mdv209openalex-snapshot
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
inferredcites →https://doi.org/10.1093/annonc/mdw389.03openalex-snapshot
Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
inferredcites →https://doi.org/10.1093/annonc/mdw389.05openalex-snapshot
A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy
inferredcites →https://doi.org/10.1093/annonc/mdw389.08openalex-snapshot
STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT
inferredcites →https://doi.org/10.1093/annonc/mdw389.09openalex-snapshot
A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)
inferredcites →https://doi.org/10.1093/annonc/mdx386openalex-snapshot
Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod
inferredcites →https://doi.org/10.1093/annonc/mdx386.002openalex-snapshot
Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)
inferredcites →https://doi.org/10.1093/annonc/mdx386.004openalex-snapshot
Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)
inferredcites →https://doi.org/10.1093/annonc/mdx386.008openalex-snapshot
KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)
inferredcites →https://doi.org/10.1093/annonc/mdy298openalex-snapshot
A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial
inferredcites →https://doi.org/10.1093/jnci/85.4.316openalex-snapshot
Interleukin-2 Activity in Patients With Extensive Small-Cell Lung Cancer: A Phase II Trial of Cancer and Leukemia Group B
inferredcites →https://doi.org/10.1097/jto.0000000000000414openalex-snapshot
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
inferredcites →https://doi.org/10.1097/jto.0b013e318286cf88openalex-snapshot
Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches
inferredcites →https://doi.org/10.1126/scitranslmed.aac9459openalex-snapshot
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
inferredcites →https://doi.org/10.1146/annurev.immunol.26.021607.090331openalex-snapshot
PD-1 and Its Ligands in Tolerance and Immunity
inferredcites →https://doi.org/10.1158/1078-0432.ccr-03-0101openalex-snapshot
Vaccination of Small Cell Lung Cancer Patients with Polysialic Acid orN-Propionylated Polysialic Acid Conjugated to Keyhole Limpet Hemocyanin
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-0482openalex-snapshot
Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin
inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-2013openalex-snapshot
Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-1156openalex-snapshot
Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-1678openalex-snapshot
Microsatellite Instability as a Biomarker for PD-1 Blockade
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-3215openalex-snapshot
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
inferredcites →https://doi.org/10.1158/1535-7163.mct-17-0386openalex-snapshot
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
inferredcites →https://doi.org/10.1159/000453569openalex-snapshot
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
inferredcites →https://doi.org/10.1172/jci81603openalex-snapshot
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
inferredcites →https://doi.org/10.1200/jco.1994.12.11.2321openalex-snapshot
Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.
inferredcites →https://doi.org/10.1200/jco.1995.13.12.2924openalex-snapshot
Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.
inferredcites →https://doi.org/10.1200/jco.2005.17.186openalex-snapshot
Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
inferredcites →https://doi.org/10.1200/jco.2015.63.7918openalex-snapshot
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
inferredcites →https://doi.org/10.1200/jco.2016.34.15_suppl.8566openalex-snapshot
Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC).
inferredcites →https://doi.org/10.1200/jco.2016.34.15_suppl.tps8578openalex-snapshot
CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).
inferredcites →https://doi.org/10.1200/jco.2016.34.15_suppl.tps8579openalex-snapshot
CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC).
inferredcites →https://doi.org/10.1200/jco.2016.67.6601openalex-snapshot
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.8503openalex-snapshot
Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.8569openalex-snapshot
Small cell lung cancer: The immune microenvironment and prognostic impact of checkpoint expression.
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.tps8585openalex-snapshot
A phase II, open-label, multi-arm study of novel combinations of immunotherapies or DDR inhibitors in platinum-refractory, extensive disease small-cell lung cancer (ED-SCLC): BALTIC.
inferredcites →https://doi.org/10.1200/jco.2017.72.5069openalex-snapshot
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
inferredcites →https://doi.org/10.1200/jco.2018.36.15_suppl.8506openalex-snapshot
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
inferredcites →https://doi.org/10.1200/jco.2018.36.15_suppl.8507openalex-snapshot
Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study.
inferredcites →https://doi.org/10.1371/journal.pone.0179170openalex-snapshot
A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy
inferredcites →https://doi.org/10.1378/chest.12-0681openalex-snapshot
Histologic Assessment of Tumor-Associated CD45+ Cell Numbers Is an Independent Predictor of Prognosis in Small Cell Lung Cancer
inferredcites →https://doi.org/10.1517/14712598.2010.484801openalex-snapshot
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
inferredcites →https://doi.org/10.21037/tlcr.2017.10.04openalex-snapshot
Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?
inferredcites →https://doi.org/10.2147/dddt.s43184openalex-snapshot
Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a Phase II, randomized study
inferredcites →https://doi.org/10.2174/156800910791054167openalex-snapshot
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
inferredcites →https://doi.org/10.3389/fimmu.2017.01679openalex-snapshot
Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
inferredcites →https://doi.org/10.3978/j.issn.2218-6751.2016.01.13openalex-snapshot
Treatment for small cell lung cancer, where are we now?-a review.
inferredcites →https://doi.org/10.4049/jimmunol.144.4.1382openalex-snapshot
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.
inferredcites →https://doi.org/10.4103/ctm.ctm_26_17openalex-snapshot
“Eating” Cancer cells by blocking CD47 signaling: Cancer therapy by targeting the innate immune checkpoint
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4154104openalex-extracted
Development of an Updated, Standardized, Patient-Centered Outcome Set for Lung Cancer
inferred← citeshttps://doi.org/10.1002/cac2.12538openalex-snapshot
Conserved immuno‐collagenic subtypes predict response to immune checkpoint blockade
inferred← citeshttps://doi.org/10.1002/cam4.4402openalex-snapshot
Identification of a prognostic immune‐related signature for small cell lung cancer
inferred← citeshttps://doi.org/10.1002/cam4.5659openalex-snapshot
Advances in immune checkpoint inhibitors therapy for small cell lung cancer
inferred← citeshttps://doi.org/10.1007/978-981-33-6827-9_10openalex-snapshot
Modulation of Signaling Pathways by Immunotherapeutics in Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-981-99-7141-1_3openalex-snapshot
Evolution of Lung Cancer Treatment from Classical Chemotherapy to Advanced Immunotherapy
inferred← citeshttps://doi.org/10.1007/s00129-022-04941-6openalex-snapshot
Nebenwirkungsmanagement immunonkologischer Therapien – was gibt es zu beachten?
inferred← citeshttps://doi.org/10.1007/s00432-021-03798-xopenalex-snapshot
Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants
inferred← citeshttps://doi.org/10.1007/s10549-025-07854-9openalex-snapshot
Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy
inferred← citeshttps://doi.org/10.1007/s11864-022-00949-1openalex-snapshot
Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective
inferred← citeshttps://doi.org/10.1007/s11912-023-01465-7openalex-snapshot
Novel Therapeutic Options for Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/s12032-023-02005-wopenalex-snapshot
A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
inferred← citeshttps://doi.org/10.1007/s12325-021-01909-1openalex-snapshot
Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
inferred← citeshttps://doi.org/10.1007/s12672-024-01119-5openalex-snapshot
Immunotherapy for small cell lung cancer: the current state and future trajectories
inferred← citeshttps://doi.org/10.1007/s40265-019-01240-8openalex-snapshot
In Search of the Long-Desired ‘Copernican Therapeutic Revolution’ in Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/s40265-020-01398-6openalex-snapshot
Atezolizumab: A Review in Extensive-Stage SCLC
inferred← citeshttps://doi.org/10.1016/j.addr.2023.114831openalex-snapshot
Aerosol pulmonary immune engineering
inferred← citeshttps://doi.org/10.1016/j.bioadv.2024.213839openalex-snapshot
Aerosolization of poly(sulfobetaine) microparticles that encapsulate therapeutic antibodies
inferred← citeshttps://doi.org/10.1016/j.chest.2021.02.032openalex-snapshot
Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.clinthera.2020.12.017openalex-snapshot
Meta-analysis of the Efficacy and Tolerability of Immune Checkpoint Inhibitors Combined With Chemotherapy in First-line Treatment of Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.cllc.2018.12.019openalex-snapshot
Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133
inferred← citeshttps://doi.org/10.1016/j.clon.2024.06.056openalex-snapshot
Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2025.104872openalex-snapshot
Recent advances in nanoparticles with a PD-L1-based therapy combination of chemotherapy for lung cancer
inferred← citeshttps://doi.org/10.1016/j.ctrv.2024.102798openalex-snapshot
Challenges and future perspectives for the use of temozolomide in the treatment of SCLC
inferred← citeshttps://doi.org/10.1016/j.currproblcancer.2020.100613openalex-snapshot
The Risk of Second Primary Malignancies in Patients With Lung Neuroendocrine Tumors: A Population-Based Study on SEER Database
inferred← citeshttps://doi.org/10.1016/j.ejphar.2021.174298openalex-snapshot
Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.ijrobp.2021.05.003openalex-snapshot
Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial
inferred← citeshttps://doi.org/10.1016/j.jare.2023.10.009openalex-snapshot
Deciphering the role of CD47 in cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.jtho.2019.11.031openalex-snapshot
Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2021.100266openalex-snapshot
Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis
inferred← citeshttps://doi.org/10.1016/j.lungcan.2020.11.002openalex-snapshot
Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants
inferred← citeshttps://doi.org/10.1016/j.lungcan.2022.08.015openalex-snapshot
Real-world evidence for immunotherapy in the first line setting in small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2022.08.021openalex-snapshot
Development of an updated, standardized, patient-centered outcome set for lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2022.11.014openalex-snapshot
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification
inferred← citeshttps://doi.org/10.1016/j.lungcan.2023.02.003openalex-snapshot
Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis
inferred← citeshttps://doi.org/10.1016/j.tranon.2023.101697openalex-snapshot
Heterogeneous distribution pattern of CD3+ tumor-infiltrated lymphocytes (TILs) and high combined positive score (CPS) favored the prognosis of resected early stage small-cell lung cancer
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.3c01040openalex-snapshot
Immunotherapy Study on Non-small-Cell Lung Cancer (NSCLC) Combined with Cytotoxic T Cells and miRNA34a
inferred← citeshttps://doi.org/10.1021/acsami.3c01607openalex-snapshot
Programmable DNA Circuit-Facilitated Determination of Circulating Extracellular Vesicle PD-L1 for Lung Cancer Diagnosis and Immunotherapy Response Prediction
inferred← citeshttps://doi.org/10.1038/s41392-024-01974-2openalex-snapshot
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial
inferred← citeshttps://doi.org/10.1038/s41598-021-02582-8openalex-snapshot
Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain)
inferred← citeshttps://doi.org/10.1038/s41598-025-23649-wopenalex-snapshot
Organ-based tumor distribution for predicting prognosis in small-cell lung cancer using fluorodeoxyglucose positron emission tomography/computed tomography
inferred← citeshttps://doi.org/10.1053/j.gastro.2020.03.074openalex-snapshot
Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice
inferred← citeshttps://doi.org/10.1080/14728214.2020.1798929openalex-snapshot
Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1080/14728222.2020.1723548openalex-snapshot
MYC, MYCL, and MYCN as therapeutic targets in lung cancer
inferred← citeshttps://doi.org/10.1080/17476348.2021.1987887openalex-snapshot
Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer
inferred← citeshttps://doi.org/10.1080/17512433.2021.1911640openalex-snapshot
Immunotherapy for the treatment of metastatic small cell lung cancer: Focus on pembrolizumab
inferred← citeshttps://doi.org/10.1097/md.0000000000027121openalex-snapshot
Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer
inferred← citeshttps://doi.org/10.1097/md.0000000000027138openalex-snapshot
Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer
inferred← citeshttps://doi.org/10.1101/gad.338228.120openalex-snapshot
Cells of origin of lung cancers: lessons from mouse studies
inferred← citeshttps://doi.org/10.1111/1759-7714.14679openalex-snapshot
Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer
inferred← citeshttps://doi.org/10.1111/1759-7714.14712openalex-snapshot
Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade
inferred← citeshttps://doi.org/10.1155/2019/6860432openalex-snapshot
The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-23-1159openalex-snapshot
Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1177/03008916211022834openalex-snapshot
Emergency rigid bronchoscopy and immunotherapy: successful combination in dramatic respiratory debut of pulmonary adenocarcinoma
inferred← citeshttps://doi.org/10.1186/s12865-023-00553-4openalex-snapshot
Higher cytotoxic activities of CD8+ T cells and natural killer cells from peripheral blood of early diagnosed lung cancer patients
inferred← citeshttps://doi.org/10.1186/s12880-021-00602-7openalex-snapshot
Differentiation of brain metastases from small and non-small lung cancers using apparent diffusion coefficient (ADC) maps
inferred← citeshttps://doi.org/10.1186/s12890-023-02832-7openalex-snapshot
Development and validation of prognostic models for small cell lung cancer patients with liver metastasis: a SEER population-based study
inferred← citeshttps://doi.org/10.1212/nxi.0000000000000604openalex-snapshot
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.14720/abs.65.1.15941openalex-snapshot
Nikotinski acetilholinski receptor kot farmakološka tarča pri pljučnem raku
inferred← citeshttps://doi.org/10.1634/theoncologist.2020-0193openalex-snapshot
Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.18053/jctres.07.202101.001openalex-snapshot
Immunotherapy in non-small cell lung cancer: update and new insights
inferred← citeshttps://doi.org/10.21037/apm-21-443openalex-snapshot
Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer: a phase 2 single-arm multicenter open-label trial
inferred← citeshttps://doi.org/10.21037/atm-21-68openalex-snapshot
A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer
inferred← citeshttps://doi.org/10.21037/jtd-23-1494openalex-snapshot
Characteristics and patient-reported outcomes of long-term lung cancer survivors
inferred← citeshttps://doi.org/10.21203/rs.3.rs-9471666/v1openalex-snapshot
Phase II trial of Pembrolizumab and Lenvatinib in Advanced Neuroendocrine Prostate Cancer (PLANE-PC)
inferred← citeshttps://doi.org/10.2147/ijgm.s337316openalex-snapshot
Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.2174/0109298673278897231229121524openalex-snapshot
The use of Isoflavones as Lung Cancer Chemoprevention Agents and their Implications in Treatment through Radio Sensitization
inferred← citeshttps://doi.org/10.2174/1566524023666230817115937openalex-snapshot
Hydroquinidine Demonstrates Remarkable Antineoplastic Effects on Non-small Cell Lung Cancer Cells
inferred← citeshttps://doi.org/10.2174/1871520622666220519102948openalex-snapshot
Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy
inferred← citeshttps://doi.org/10.2214/ajr.20.23025openalex-snapshot
Role of Key Guidelines in an Era of Precision Oncology: A Primer for the Radiologist
inferred← citeshttps://doi.org/10.32948/ajo.2023.02.02openalex-snapshot
Characteristics and outcomes of patients with small cell lung cancer - findings from a New Zealand SACT database
inferred← citeshttps://doi.org/10.33590/emjoncol/19-00145openalex-snapshot
Precision Medicine in Lung Cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1197044openalex-snapshot
Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis
inferred← citeshttps://doi.org/10.3389/fonc.2020.01409openalex-snapshot
Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade Glioma
inferred← citeshttps://doi.org/10.3389/fonc.2021.604227openalex-snapshot
Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.3389/fonc.2023.1151769openalex-snapshot
Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.3389/fphar.2021.746853openalex-snapshot
Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation
inferred← citeshttps://doi.org/10.3389/pore.2023.1611086openalex-snapshot
Potential predictors of immunotherapy in small cell lung cancer
inferred← citeshttps://doi.org/10.3390/cancers11040533openalex-snapshot
The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer—Ways of Enhancing Immunotherapy Action
inferred← citeshttps://doi.org/10.3390/cancers12123629openalex-snapshot
Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
inferred← citeshttps://doi.org/10.3390/cancers13030506openalex-snapshot
Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.3390/cancers13061187openalex-snapshot
Molecular Signature of Small Cell Lung Cancer after Treatment Failure: The MCM Complex as Therapeutic Target
inferred← citeshttps://doi.org/10.3390/cancers14112680openalex-snapshot
Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review
inferred← citeshttps://doi.org/10.3390/curroncol31100469openalex-snapshot
Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review
inferred← citeshttps://doi.org/10.3390/ijms222413508openalex-snapshot
Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack?
inferred← citeshttps://doi.org/10.3390/jcm14176133openalex-snapshot
Lung Toxicity from Immune Checkpoint Inhibitors: A Diagnostic Approach
inferred← citeshttps://doi.org/10.3390/jcm9123860openalex-snapshot
Artificial Intelligence Tools for Refining Lung Cancer Screening
inferred← citeshttps://doi.org/10.3390/onco1010002openalex-snapshot
The Impact of Immune Checkpoint-Inhibitors Therapy in Urinary Bladder Cancer
inferred← citeshttps://doi.org/10.3390/vaccines9070689openalex-snapshot
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
inferred← citeshttps://doi.org/10.36348/sjodr.2023.v08i10.001openalex-snapshot
Oral Lesions Associated with Immune Checkpoint Inhibitors in Cancer Therapy: An Emerging Entity Oral Healthcare Professionals Should Comprehend
inferred← citeshttps://doi.org/10.37499/pia.714openalex-snapshot
Smulkiųjų ląstelių plaučių vėžio imunoterapija
inferred← citeshttps://doi.org/10.3779/j.issn.1009-3419.2019.06.07openalex-snapshot
[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
inferred← citeshttps://doi.org/10.3779/j.issn.1009-3419.2020.105.02openalex-snapshot
[Immunotherapy Advances in Small Cell Lung Cancer].
inferred← citeshttps://doi.org/10.4018/978-1-7998-6530-8.ch015openalex-snapshot
Precision Medicine in Cancer
inferred← citeshttps://doi.org/10.4103/jco.jco_12_19openalex-snapshot
Immune checkpoint inhibitors in the driver’s seat: Evaluating the evolving evidence in the treatment of extensive-stage small-cell lung cancer
inferred← citeshttps://doi.org/10.55729/2000-9666.1037openalex-snapshot
Electrolyte Abnormalities Associated With The Use of Atezolizumab – A Systematic Review
inferred← citeshttps://doi.org/10.5578/tt.69278openalex-snapshot
Immunotherapy and multidisciplinary approach to treatment in lung cancer
inferred← citeshttps://doi.org/10.5603/ocp.2022.0011openalex-snapshot
Immune checkpoint inhibitors in the first-line treatment of metastatic small-cell lung cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.14429195openalex-snapshot
Additional file 1 of Differentiation of brain metastases from small and non-small lung cancers using apparent diffusion coefficient (ADC) maps
inferred← citeshttps://doi.org/10.6084/m9.figshare.14429198openalex-snapshot
Additional file 2 of Differentiation of brain metastases from small and non-small lung cancers using apparent diffusion coefficient (ADC) maps
inferred← citeshttps://doi.org/10.6084/m9.figshare.24946381openalex-snapshot
Additional file 1 of Development and validation of prognostic models for small cell lung cancer patients with liver metastasis: a SEER population-based study
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.